Primigravida in Labour PainsNCT01205360
Dosing Strategies for Automated Mandatory Intermittent Boluses Technique for Epidural Labour Analgesia
A study testing Bupivacaine-Fentanyl Mixture in people with Primigravida in Labour Pains, run by Pravara Institute of Medical Sciences University.
Trial summary
The purpose of this study is to determine how manipulation of the programmed intermittent time interval and volume influences total drug use, quality of analgesia, and patient satisfaction during maintenance of labor analgesia. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Primigravida in Labour Pains
- What is being tested?
- Bupivacaine-Fentanyl Mixture
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Aug 2010to Oct 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Full term women in spontaneous labor.
- Gestation greater than or equal to 37 weeks.
- Primigravida.
- Age group between 18 Years to 45 Years.
- ASA grade I or II
- Not having any complicated pregnancy
- Not having any systemic disorders.
Who cannot join
- Not willing for Epidural analgesia.
- Unwilling to get enrolled in this study.
- Systemic disorder like diabetes mellitus, hypertension and heart disease, spine deformity, blood coagulation disorder, bad obstetric history and foetal abnormity.
- Multiple-pregnancy or abnormal presentation.
- Complicated pregnancy like pregnancy induced hypertension, placenta previa, abruptio placenta.
- Cervical dilatation less than 2 or greater than 5 at time of initiation of neuraxial analgesia.
- Chronic analgesic medications
- Systemic opioid labor analgesia prior to the initiation of neuraxial labor analgesia.
About this study
Official title: A Randomized, Control Study to Evaluate Dosing Strategies for Automated Mandatory Intermittent Boluses Technique for Epidural Labour Analgesia
The purpose of this study is to determine how manipulation of the programmed intermittent time interval and volume influences total drug use, quality of analgesia, and patient satisfaction during maintenance of labor analgesia.
Read the detailed description
Research for the ideal technique of maintaining epidural analgesia after the initial-level block is ongoing. Continuous infusion techniques, use of more dilute solutions , PCEA , and different techniques of PCEA like background dosing, none, fixed infusion as background, variable infusion (computer-integrated), programmed intermittent boluses (PIEBs) and automated mandatory boluses, have been used. Automated systems designed to administer a small bolus dose of anaesthetic at programmable intervals may combine the advantages of both manual bolus and continuous epidural infusion (CEI) systems.
Wong et al compared a PIEB (6 ml of bolus every 30 minutes) with CEI with the assumption that small frequent boluses may avoid wide fluctuations in sensory levels, commonly seen with traditional manually administered intermittent boluses and at the same time reduce the total anesthetic dose as in CEI. Chua and Sia showed that Pain scores were lower and the time to first manual epidural rescue bolus was longer in parturients assigned to intermittent boluses compared to continuous epidural infusion of the same solution in the intermittent group. Fettes and colleagues found that patients required a lower total drug dose and fewer manual bolus injections when epidural labor analgesia was maintained with automated intermittent boluses of ropivacaine compared to a continuous infusion. Solutions injected into the epidural space tend to spread more evenly when injected as a bolus, as compared to a continuous infusion. Furthermore, studies of epidural opioid analgesia suggest that epidural bolus administration of lipid soluble opioids (e.g., fentanyl) results in segmental spinal opioid analgesia, whereas continuous opioid epidural infusion results in systemic opioid analgesia. The analgesic effects of both epidural fentanyl infusion and epidural fentanyl bolus were evaluated using a volunteer, double blind, cross-over designs study. Taken together, the results of these studies suggest that further studies of automated intermittent bolus injections are indicated, in particular, studies of the optimal bolus time interval and volume. At one end of the spectrum, a short interval/low volume protocol may mimic a continuous infusion. At the other end of the spectrum, a long interval/large volume may negate the inherent safety of a continuous infusion. The purpose of the proposed study is to determine how manipulation of the programmed intermittent time interval and volume influences total drug use, quality of analgesia, and patient satisfaction during maintenance of labor analgesia.
Current pump technology does not support programmed intermittent bolus administration. The investigators encouraged the manufacturer to develop these features indigenously and incorporate them in presently available infusion pumps.
Methods:
Study will be carried out in randomly selected sixty uncomplicated full term pregnant patients, in active labour.
After written, informed, valid consent, and administration of five hundred millilitres of Ringer's lactate intravenously as a preload, epidural catheter will be inserted under aseptic conditions in an L2-L3 or L3-L4 space through 16 G Tuohy's needle. Epidural space will be identified through the loss-of-resistance technique. The catheter will be placed, cephaled, two spaces (3 to 4 cm) above the point of insertion.
Its position will be confirmed by administering a test dose of 3 ml of lignocaine (2%) with adrenaline.
A loading-dose mixture of 10 ml of bupivacaine (0.125%) and fentanyl (2 µg/ml) will be administered epidurally targeting initial sensory block to T 10 level .Additional doses of Inj.bupivacaine will be administered if required.
Infusion pump will be attached to the catheter and all patients will be randomly divided in three groups.
- Group 3-15 : Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses
- Group 4-20: Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
- Group 6-30: Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
Randomization will be carried out based on blocking. Blocks of size 3 with treatment allocation of 1:1:1 for group I, group II and group III will be created. A block of 3 patients will be assigned to one of the blocks created.
For blinding of patient as well observer, the settings of infusion pump will be hidden by covering it with cloth.
The level of sensory blockade will be tested by a pinprick method in midline and motor blockade will be tested with the modified Bromage scale used by Breen et al.
A single dose will be omitted if the sensory block goes higher than T7 or the motor blockade goes below score 4 as per the Bromage scale. Similarly additional top-ups of 3 ml of 0.125 % bupivacaine with fentanyl 2 micrograms / ml will be administered if patients get severe break through pain (VAS pain score > 3)
. Maternal parameters like pulse rate, blood pressure and respiratory rate will be monitored frequently. FHR will be monitored through tococardiography. Bearing-down ability will be assessed by asking the patients about the perception of the urge to bear down. Neonates will be assessed by Apgar score at 1 minute and 5 minutes after birth. The patients will be observed for any side effects or complications, such as pruritus, nausea and vomiting, hypotension, a headache, sedation and respiratory depression. Labour analgesic drug administration will be stopped after delivery and the duration of labour analgesia will be recorded. The total dose of bupivacaine and fentanyl will be calculated. The quality of analgesia will be assessed hourly. The patients will be asked about pain relief during the last hour and will be given scores as follows:
- 0 = No pain, pressure or tightening sensation
- 1 = Awareness of pressure or tightening sensation but not painful
- 2 = Slight pain or pressure sensation but not distressing
- 3 = Distressing pain or pressure sensation Even when the patients scored higher for a very short period, the higher score will be recorded for that hour. All the patients will be interviewed within 24 hours of delivery by an anaesthetist colleague who will unaware of the technique used and recorded a linear visual analogue scale (VAS) pain score on the patient's opinion about overall efficacy of analgesia. On this scale, 0 cm will indicate no pain and 10 cm will indicate worst pain. They will also ask about the level of their satisfaction regarding the quality of analgesia, which will be graded as 'excellent', 'good' and 'bad'.
Statistical analysis will be carried out with Stata 11.
- Conditions
- Primigravida in Labour Pains
- Being tested
- Bupivacaine-Fentanyl Mixture
- Keywords
- Analgesia, labour;, Analgesic techniques, epidural;, Drug delivery, intermittent bolus;, Anesthetics local, Bupivacaine;, Analgesics opioid, Fentanyl;
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bupivacaine-Fentanyl MixtureDrug
Also called Bupivacaine-Fentanyl
Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
Bupivacaine-Fentanyl MixtureDrug
Also called Bupivacaine-Fentanyl
Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
Bupivacaine-Fentanyl MixtureDrug
Also called Bupivacaine-Fentanyl
Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Bupivacaine-Fentanyl (3-15) | Active comparator | Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses. Receives: Drug: Bupivacaine-Fentanyl Mixture |
| Bupivacaine-Fentanyl (4-20) | Experimental | Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes. Receives: Drug: Bupivacaine-Fentanyl Mixture |
| Bupivacaine-Fentanyl (6-30) | Experimental | Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes. Receives: Drug: Bupivacaine-Fentanyl Mixture |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total epidural bupivacaine dose
Labour analgesic drug administration will be stopped after delivery and the total dose of bupivacaine will be calculated.
Measured: 48 hours
Secondary outcomes (9)
Demographics
Age, Height,Weight
Measured: 10 Minutes
Quality of analgesia (Cumulative analgesia scores )
The quality of analgesia will be assessed hourly. The patients will be asked about pain relief during the last hour and will be given scores as follows:
0 = No pain, pressure or tightening sensation
- = Awareness of pressure or tightening sensation but not painful
- = Slight pain or pressure sensation but not distressing
- = Distressing pain or pressure sensation Even when the patients scored higher for a very short period, the higher score will be recorded for that hour. Cumulative analgesia scores will be measured.
Measured: Every Hour
Level of analgesia (VAS score)
All patients will be interviewed within 24 hours of delivery by an anaesthetist colleague who will unaware of the technique used and recorded a linear visual analogue scale (VAS) pain score on the patient's opinion about overall efficacy of analgesia. On this scale, 0 cm will indicate no pain and 10 cm will indicate worst pain.
Measured: 48 hours
Maternal satisfaction
All the patients will be interviewed within 24 hours of delivery by an anaesthetist colleague who will unaware of the technique used and They will also ask about the level of their satisfaction regarding the quality of analgesia, which will be graded as 'excellent', 'good' and 'bad'.
Measured: 48 hours
No.of doses omitted
A single dose will be omitted if the sensory block goes higher than T7 or the motor blockade goes below score 4 as per the Bromage scale.
Measured: 48 hours
No.of Additional top-ups required
Additional top-ups of 3 ml of 0.125 % bupivacaine with fentanyl 2 micrograms / ml will be administered if patients get severe break through pain (VAS pain score > 3)
Measured: 48 hours
Duration of labour
Labour analgesic drug administration will be stopped after delivery and the duration of labour will be recorded.
Measured: 48 hours
Maternal Safety
Maternal parameters like pulse rate, blood pressure and respiratory rate will be monitored frequently.The patients will be observed for any side effects or complications, such as pruritus, nausea and vomiting, hypotension, a headache, sedation and respiratory depression.
Measured: 48 hours
Foetal Safety
FHR will be monitored through tococardiography.Neonates will be assessed by Apgar score at 1 minute and 5 minutes after birth.
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2010 (estimated)
- Study startAug 2010
- Primary completionJul 2012 (estimated)
- Study completionOct 2012 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primigravida in Labour PainsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pravara Institute of Medical Sciences University
- Sponsor type
- University, hospital or other
- Investigators
- Dr.Mandar V Galande, MBBS, Principal investigator, Pravara Rural HospitalDr.Ramchandra V Shidhaye, MD DA, Principal investigator, Pravara Rural HospitalDr.Devdas S Divekar, MD DA, Principal investigator, Pravara Rural Hospital, Loni
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01205360
- Sponsor's protocol ID
- abcd 2
- Status last verified
- Sep 2010
- First submitted
- 17 Sep 2010
- Last updated
- 21 Sep 2017
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Control Study to Evaluate Dosing Strategies for Automated Mandatory Intermittent Boluses Technique for Epidural Labour Analgesia
- ClinicalTrials.gov ID
- NCT01205360
- Acronym / sponsor ID
- abcd 2
- Conditions
- Primigravida in Labour Pains
- Keywords
- Analgesia, labour;, Analgesic techniques, epidural;, Drug delivery, intermittent bolus;, Anesthetics local, Bupivacaine;, Analgesics opioid, Fentanyl;
- Study type
- Interventional
- Recruitment status
- Withdrawn
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Pravara Institute of Medical Sciences UniversityUniversity, hospital or other
- Study start
- Aug 2010
- Primary completion
- Jul 2012 (estimated)
- Study completion
- Oct 2012 (estimated)
- First posted
- 20 Sep 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine how manipulation of the programmed intermittent time interval and volume influences total drug use, quality of analgesia, and patient satisfaction during maintenance of labor analgesia.
Detailed description
Research for the ideal technique of maintaining epidural analgesia after the initial-level block is ongoing. Continuous infusion techniques, use of more dilute solutions , PCEA , and different techniques of PCEA like background dosing, none, fixed infusion as background, variable infusion (computer-integrated), programmed intermittent boluses (PIEBs) and automated mandatory boluses, have been used. Automated systems designed to administer a small bolus dose of anaesthetic at programmable intervals may combine the advantages of both manual bolus and continuous epidural infusion (CEI) systems.
Wong et al compared a PIEB (6 ml of bolus every 30 minutes) with CEI with the assumption that small frequent boluses may avoid wide fluctuations in sensory levels, commonly seen with traditional manually administered intermittent boluses and at the same time reduce the total anesthetic dose as in CEI. Chua and Sia showed that Pain scores were lower and the time to first manual epidural rescue bolus was longer in parturients assigned to intermittent boluses compared to continuous epidural infusion of the same solution in the intermittent group. Fettes and colleagues found that patients required a lower total drug dose and fewer manual bolus injections when epidural labor analgesia was maintained with automated intermittent boluses of ropivacaine compared to a continuous infusion. Solutions injected into the epidural space tend to spread more evenly when injected as a bolus, as compared to a continuous infusion. Furthermore, studies of epidural opioid analgesia suggest that epidural bolus administration of lipid soluble opioids (e.g., fentanyl) results in segmental spinal opioid analgesia, whereas continuous opioid epidural infusion results in systemic opioid analgesia. The analgesic effects of both epidural fentanyl infusion and epidural fentanyl bolus were evaluated using a volunteer, double blind, cross-over designs study. Taken together, the results of these studies suggest that further studies of automated intermittent bolus injections are indicated, in particular, studies of the optimal bolus time interval and volume. At one end of the spectrum, a short interval/low volume protocol may mimic a continuous infusion. At the other end of the spectrum, a long interval/large volume may negate the inherent safety of a continuous infusion. The purpose of the proposed study is to determine how manipulation of the programmed intermittent time interval and volume influences total drug use, quality of analgesia, and patient satisfaction during maintenance of labor analgesia.
Current pump technology does not support programmed intermittent bolus administration. The investigators encouraged the manufacturer to develop these features indigenously and incorporate them in presently available infusion pumps.
Methods:
Study will be carried out in randomly selected sixty uncomplicated full term pregnant patients, in active labour.
After written, informed, valid consent, and administration of five hundred millilitres of Ringer's lactate intravenously as a preload, epidural catheter will be inserted under aseptic conditions in an L2-L3 or L3-L4 space through 16 G Tuohy's needle. Epidural space will be identified through the loss-of-resistance technique. The catheter will be placed, cephaled, two spaces (3 to 4 cm) above the point of insertion.
Its position will be confirmed by administering a test dose of 3 ml of lignocaine (2%) with adrenaline.
A loading-dose mixture of 10 ml of bupivacaine (0.125%) and fentanyl (2 µg/ml) will be administered epidurally targeting initial sensory block to T 10 level .Additional doses of Inj.bupivacaine will be administered if required.
Infusion pump will be attached to the catheter and all patients will be randomly divided in three groups.
- Group 3-15 : Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses
- Group 4-20: Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
- Group 6-30: Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
Randomization will be carried out based on blocking. Blocks of size 3 with treatment allocation of 1:1:1 for group I, group II and group III will be created. A block of 3 patients will be assigned to one of the blocks created.
For blinding of patient as well observer, the settings of infusion pump will be hidden by covering it with cloth.
The level of sensory blockade will be tested by a pinprick method in midline and motor blockade will be tested with the modified Bromage scale used by Breen et al.
A single dose will be omitted if the sensory block goes higher than T7 or the motor blockade goes below score 4 as per the Bromage scale. Similarly additional top-ups of 3 ml of 0.125 % bupivacaine with fentanyl 2 micrograms / ml will be administered if patients get severe break through pain (VAS pain score > 3)
. Maternal parameters like pulse rate, blood pressure and respiratory rate will be monitored frequently. FHR will be monitored through tococardiography. Bearing-down ability will be assessed by asking the patients about the perception of the urge to bear down. Neonates will be assessed by Apgar score at 1 minute and 5 minutes after birth. The patients will be observed for any side effects or complications, such as pruritus, nausea and vomiting, hypotension, a headache, sedation and respiratory depression. Labour analgesic drug administration will be stopped after delivery and the duration of labour analgesia will be recorded. The total dose of bupivacaine and fentanyl will be calculated. The quality of analgesia will be assessed hourly. The patients will be asked about pain relief during the last hour and will be given scores as follows:
- 0 = No pain, pressure or tightening sensation
- 1 = Awareness of pressure or tightening sensation but not painful
- 2 = Slight pain or pressure sensation but not distressing
- 3 = Distressing pain or pressure sensation Even when the patients scored higher for a very short period, the higher score will be recorded for that hour. All the patients will be interviewed within 24 hours of delivery by an anaesthetist colleague who will unaware of the technique used and recorded a linear visual analogue scale (VAS) pain score on the patient's opinion about overall efficacy of analgesia. On this scale, 0 cm will indicate no pain and 10 cm will indicate worst pain. They will also ask about the level of their satisfaction regarding the quality of analgesia, which will be graded as 'excellent', 'good' and 'bad'.
Statistical analysis will be carried out with Stata 11.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Bupivacaine-Fentanyl (3-15) | Active comparator | Drug: Bupivacaine-Fentanyl MixtureThree millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses. |
| Bupivacaine-Fentanyl (4-20) | Experimental | Drug: Bupivacaine-Fentanyl MixtureFour millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes. |
| Bupivacaine-Fentanyl (6-30) | Experimental | Drug: Bupivacaine-Fentanyl MixtureSix millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Full term women in spontaneous labor.
- Gestation greater than or equal to 37 weeks.
- Primigravida.
- Age group between 18 Years to 45 Years.
- ASA grade I or II
Key exclusion criteria (8 listed)
- Not willing for Epidural analgesia.
- Unwilling to get enrolled in this study.
- Systemic disorder like diabetes mellitus, hypertension and heart disease, spine deformity, blood coagulation disorder, bad obstetric history and foetal abnormity.
- Multiple-pregnancy or abnormal presentation.
- Complicated pregnancy like pregnancy induced hypertension, placenta previa, abruptio placenta.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bupivacaine-Fentanyl MixtureAlso: Bupivacaine-FentanylThree millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses. | Drug | Bupivacaine-Fentanyl (3-15) |
| Bupivacaine-Fentanyl MixtureAlso: Bupivacaine-FentanylFour millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes. | Drug | Bupivacaine-Fentanyl (4-20) |
| Bupivacaine-Fentanyl MixtureAlso: Bupivacaine-FentanylSix millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes. | Drug | Bupivacaine-Fentanyl (6-30) |
Primary outcome
Total epidural bupivacaine dose
Time frame: 48 hours
Labour analgesic drug administration will be stopped after delivery and the total dose of bupivacaine will be calculated.
9 secondary outcomes
Demographics
Time frame: 10 Minutes
Quality of analgesia (Cumulative analgesia scores )
Time frame: Every Hour
Level of analgesia (VAS score)
Time frame: 48 hours
Maternal satisfaction
Time frame: 48 hours
No.of doses omitted
Time frame: 48 hours
No.of Additional top-ups required
Time frame: 48 hours
Duration of labour
Time frame: 48 hours
Maternal Safety
Time frame: 48 hours
Foetal Safety
Time frame: 48 hours
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2017.
Related trials for Primigravida in Labour Pains
Recruiting
Effects of Midwife-guided biırth Affirmation Cards on Labor Process and Experience ın Primigravidas
Duration of Labor, Labor Pain
Not yet recruiting
Comparison of Dural Puncture Epidural Versus Conventional Epidural for Labour Analgesia in Primigravida
Labor Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr.Mandar V Galande, MBBS principal investigator
Pravara Rural Hospital
Dr.Ramchandra V Shidhaye, MD DA principal investigator
Pravara Rural Hospital
Dr.Devdas S Divekar, MD DA principal investigator
Pravara Rural Hospital, Loni
Questions about this trial
What is this clinical trial studying?
A study testing Bupivacaine-Fentanyl Mixture in people with Primigravida in Labour Pains, run by Pravara Institute of Medical Sciences University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 21 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total epidural bupivacaine dose (time frame: 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2017.